妊娠期接种2019冠状病毒病(COVID-19)疫苗后的产科并发症与出生结局
这项回顾性队列研究纳入2021年6月1日至2022年1月31年间八个综合医疗系统的55,591例单胎活产妊娠,其中23,517例(42.3%)孕期接种了一剂或两剂mRNA COVID-19疫苗。倾向匹配分析显示,接种与早产风险降低相关(aHR 0.89;95% CI,0.83-0.94),而未增加小于胎龄儿、妊娠期糖尿病、妊娠期高血压及子痫前期-子痫-HELLP综合征的风险。
要点
- 孕期接种mRNA COVID-19疫苗与早产风险降低相关(aHR 0.89;95% CI,0.83-0.94)。
- 接种未增加小于胎龄儿风险(aHR 1.06;95% CI,0.99-1.13)。
- 接种未增加妊娠期糖尿病、妊娠期高血压及子痫前期-子痫-HELLP综合征风险。
核心结论
- 孕期接种mRNA COVID-19疫苗与不良妊娠结局风险增加无关,该信息有助于患者和临床医生在孕期考虑COVID-19疫苗接种。
研究设计与样本
- 回顾性队列研究,纳入2021年6月1日至2022年1月31日间八个综合医疗系统(疫苗安全数据链)中单胎活产妊娠者,共55,591例符合纳入条件。
- 疫苗暴露定义为孕期接种一剂或两剂mRNA COVID-19疫苗(基础免疫系列),将接种者与倾向匹配的未暴露妊娠者进行比较。
主要发现
- 55,591例中23,517例(42.3%)孕期接种了一剂或两剂mRNA COVID-19疫苗。
- 接种组早产率6.4/100 vs 未接种组7.7/100,aHR 0.89;95% CI,0.83-0.94。
- 小于胎龄儿率接种组8.3/100 vs 未接种组7.4/100,aHR 1.06,95% CI,0.99-1.13。
- 妊娠期糖尿病率接种组11.9/100 vs 未接种组10.6/100,aRR 1.00,95% CI,0.90-1.10。
- 妊娠期高血压率接种组10.8/100 vs 未接种组9.9/100,aRR 1.08,95% CI,0.96-1.22;子痫前期-子痫-HELLP综合征率接种组8.9/100 vs 未接种组8.4/100,aRR 1.10,95% CI,0.97-1.24。
关键数值与推荐
- 早产定义为妊娠37周前分娩;小于胎龄儿、妊娠期糖尿病、妊娠期高血压及子痫前期-子痫-HELLP综合征按原文定义。
- 早产和小于胎龄儿使用时间依赖协变量Cox模型估计aHR,妊娠期糖尿病、妊娠期高血压及子痫前期-子痫-HELLP综合征使用稳健方差泊松回归估计aRR。
临床怎么用
- 原文结论指出孕期接种mRNA COVID-19疫苗与不良妊娠结局风险增加无关,该信息有助于患者和临床医生在孕期考虑COVID-19疫苗接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between antenatal messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination and risk of adverse pregnancy outcomes. METHODS: This was a retrospective cohort study of individuals with singleton pregnancies with live deliveries between June 1, 2021, and January 31, 2022, with data available from eight integrated health care systems in the Vaccine Safety Datalink. Vaccine exposure was defined as receipt of one or two mRNA COVID-19 vaccine doses (primary series) during pregnancy. Outcomes were preterm birth (PTB) before 37 weeks of gestation, small-for-gestational age (SGA) neonates, gestational diabetes mellitus (GDM), gestational hypertension, and preeclampsia-eclampsia-HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Outcomes in individuals vaccinated were compared with those in propensity-matched individuals with unexposed pregnancies. Adjusted hazard ratios (aHRs) and 95% CIs were estimated for PTB and SGA using a time-dependent covariate Cox model, and adjusted relative risks (aRRs) were estimated for GDM, gestational hypertension, and preeclampsia-eclampsia-HELLP syndrome using Poisson regression with robust variance. RESULTS: Among 55,591 individuals eligible for inclusion, 23,517 (42.3%) received one or two mRNA COVID-19 vaccine doses during pregnancy. Receipt of mRNA COVID-19 vaccination varied by maternal age, race, Hispanic ethnicity, and history of COVID-19. Compared with no vaccination, mRNA COVID-19 vaccination was associated with a decreased risk of PTB (rate: 6.4 [vaccinated] vs 7.7 [unvaccinated] per 100, aHR 0.89; 95% CI, 0.83-0.94). Messenger RNA COVID-19 vaccination was not associated with SGA (8.3 vs 7.4 per 100; aHR 1.06, 95% CI, 0.99-1.13), GDM (11.9 vs 10.6 per 100; aRR 1.00, 95% CI, 0.90-1.10), gestational hypertension (10.8 vs 9.9 per 100; aRR 1.08, 95% CI, 0.96-1.22), or preeclampsia-eclampsia-HELLP syndrome (8.9 vs 8.4 per 100; aRR 1.10, 95% CI, 0.97-1.24). CONCLUSION: Receipt of an mRNA COVID-19 vaccine during pregnancy was not associated with an increased risk of adverse pregnancy outcomes; this information will be helpful for patients and clinicians when considering COVID-19 vaccination in pregnancy.
引用
- Vesco KK, Denoble AE, Lipkind HS, et al. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination. Obstet Gynecol. 2024. PMID: 38626447. doi:10.1097/AOG.0000000000005583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。